Chemotherapy combination for brain lymphoma
Part of Blood & lymphatic, Brain & nervous system, Cancer clinical trials.
This trial tests a combination of chemotherapy drugs to treat lymphoma that started in your brain. The goal is to see if this treatment helps without having to use whole-brain radiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 60 years old or younger.
- You have a confirmed type of lymphoma called diffuse large B-cell lymphoma that has not been treated yet.
- Your lymphoma is only in your brain or central nervous system, not elsewhere in your body.
- You are willing to sign a consent form agreeing to participate.
- You do not have another active cancer, HIV/AIDS, or allergies to the study drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of high-dose chemotherapy drugs (gemcitabine, busulfan, and thiotepa) followed by a stem cell transplant for people with primary central nervous system lymphoma. It aims to see if this treatment can improve outcomes for patients whose disease has responded to initial therapy.
This trial tests a combination of three drugs (rituximab, methotrexate, and orelabrutinib) plus a PD-1 inhibitor for newly diagnosed or relapsed central nervous system lymphoma. The goal is to see if this new combination can improve outcomes for patients with this rare type of lymphoma.
This trial tests a combination of three drugs (pomalidomide, rituximab, and methotrexate) for people who have just been diagnosed with a type of lymphoma that started in the brain or spinal cord. The goal is to see if this drug cocktail is safe and effective as a first treatment.
This trial tests a combination of radiation, immune-boosting drugs, and a targeted antibody for people newly diagnosed with primary central nervous system diffuse large B-cell lymphoma (a type of brain lymphoma). The goal is to see if this approach is safe and effective.
This Phase 2 trial studies methotrexate, tafasitamab, lenalidomide, and rituximab for primary B-cell lymphoma that starts in the brain/spinal fluid. It aims to see how well this combination works for people who cannot have certain high-dose stem cell treatment.
This trial compares two treatment combinations for newly diagnosed primary CNS lymphoma (PCNSL), a rare type of brain lymphoma. It tests whether adding a drug called PD-1 (a type of immunotherapy that helps your immune system fight cancer) to the standard chemotherapy (R-MA) improves outcomes compared to R-MA alone. Participating gives access to a novel combination that may be more effective, though it involves extra monitoring and possible immune-related side effects.
Hear when a new Primary Central Nervous System Lymphoma (PCNSL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.